EA201690793A1 - Способ получения лиофилизированной фармацевтической композиции, содержащей митомицин c - Google Patents

Способ получения лиофилизированной фармацевтической композиции, содержащей митомицин c

Info

Publication number
EA201690793A1
EA201690793A1 EA201690793A EA201690793A EA201690793A1 EA 201690793 A1 EA201690793 A1 EA 201690793A1 EA 201690793 A EA201690793 A EA 201690793A EA 201690793 A EA201690793 A EA 201690793A EA 201690793 A1 EA201690793 A1 EA 201690793A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mytomycin
pharmaceutical composition
composition containing
lyophilized pharmaceutical
obtaining lyophilized
Prior art date
Application number
EA201690793A
Other languages
English (en)
Other versions
EA036982B1 (ru
Inventor
Зонья Шульдт-Либ
Себастьян Биаллек
Инго Гуде
Михаэла Реберг
Original Assignee
Медак Гезельшафт Фюр Клинише Шпециальпрепарате Мбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49515194&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201690793(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Медак Гезельшафт Фюр Клинише Шпециальпрепарате Мбх filed Critical Медак Гезельшафт Фюр Клинише Шпециальпрепарате Мбх
Publication of EA201690793A1 publication Critical patent/EA201690793A1/ru
Publication of EA036982B1 publication Critical patent/EA036982B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к способу получения лиофилизированных композиций митомицина С, которые характеризуются превосходной стабильностью и могут быть быстро разведены до растворов.
EA201690793A 2013-10-22 2014-10-16 Способ получения лиофилизированной фармацевтической композиции, содержащей митомицин с EA036982B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13189775.3A EP2865391B1 (de) 2013-10-22 2013-10-22 Verfahren zur Herstellung einer gefriergetrockneten pharmazeutischen Zusammensetzung mit Gehalt an Mitomycin C
PCT/EP2014/072201 WO2015059023A1 (de) 2013-10-22 2014-10-16 Verfahren zur herstellung einer gefriergetrockneten pharmazeutischen zusammensetzung mit gehalt an mitomycin c

Publications (2)

Publication Number Publication Date
EA201690793A1 true EA201690793A1 (ru) 2016-08-31
EA036982B1 EA036982B1 (ru) 2021-01-22

Family

ID=49515194

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690793A EA036982B1 (ru) 2013-10-22 2014-10-16 Способ получения лиофилизированной фармацевтической композиции, содержащей митомицин с

Country Status (13)

Country Link
US (2) US10688049B2 (ru)
EP (2) EP2865391B1 (ru)
JP (2) JP6461945B2 (ru)
CN (1) CN105744957B (ru)
DK (2) DK3272361T3 (ru)
EA (1) EA036982B1 (ru)
ES (2) ES2648367T3 (ru)
HK (1) HK1208351A1 (ru)
LT (2) LT2865391T (ru)
NO (1) NO2865391T3 (ru)
PL (2) PL2865391T3 (ru)
PT (2) PT2865391T (ru)
WO (1) WO2015059023A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6706988B2 (ja) * 2016-07-20 2020-06-10 日本化薬株式会社 ボルテゾミブを含有する医薬組成物
EP3773488A4 (en) * 2018-04-05 2021-11-17 Tarveda Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS WITH A REDUCED TERT-BUTANOL CONTENT
JP2023553976A (ja) 2020-12-11 2023-12-26 ウロゲン ファーマ リミテッド がんを治療するための材料及び方法
CN113197870B (zh) * 2021-04-14 2022-07-01 健进制药有限公司 一种注射用丝裂霉素冻干制剂及其制备方法
IN202121042020A (ru) * 2021-09-17 2023-03-24
CN114557970B (zh) 2022-03-17 2023-03-31 浙江长典药物技术开发有限公司 一种眼用丝裂霉素冻干粉及其制备方法
WO2024079565A1 (en) * 2022-10-12 2024-04-18 Harshal Prabhakar Bhagwatwar Stable mitomycin concentrates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB830874A (en) 1957-04-06 1960-03-23 Kyowa Hakko Kogyo Kk A new antibiotic mitomycin c and its production by fermentation
ZA86308B (en) * 1985-02-25 1986-11-26 Bristol Myers Co In-vial deposition of 7-(dimethylaminomethylene)amino-9a-methoxy-mitosane
US5216011A (en) 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
KR100215739B1 (ko) * 1994-10-13 1999-08-16 오쿠다 기요아키 가역성열겔화 수용성 의약 조성물을 함유하는 동결건조 제제
DE19957371A1 (de) 1999-11-29 2001-06-13 Medac Klinische Spezialpraep Mitomycin C-Lösung
CA2476494C (en) 2002-02-22 2010-04-27 Schering Corporation Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
CN1712014A (zh) 2004-06-14 2005-12-28 马文·F·刘 甘草甜素的新用途
CN101204382A (zh) 2007-12-13 2008-06-25 厦门大学 植入型抗肿瘤药丝裂霉素双重缓释膜剂及其制备方法
US8168224B2 (en) 2007-12-19 2012-05-01 Beijing Shengyiyao Science & Technology Development Co., Ltd. Sodium alginate microsphere vascular embolus containing water-soluble drug and preparation and application thereof

Also Published As

Publication number Publication date
LT3272361T (lt) 2020-01-10
JP2016534060A (ja) 2016-11-04
LT2865391T (lt) 2017-11-27
PT2865391T (pt) 2017-12-22
EP2865391B1 (de) 2017-09-20
US10688049B2 (en) 2020-06-23
DK2865391T3 (da) 2017-11-20
NO2865391T3 (ru) 2018-02-17
EP3272361A1 (de) 2018-01-24
PT3272361T (pt) 2020-01-21
PL3272361T3 (pl) 2020-04-30
CN105744957A (zh) 2016-07-06
PL2865391T3 (pl) 2018-01-31
US20160256391A1 (en) 2016-09-08
CN105744957B (zh) 2019-07-02
JP6869941B2 (ja) 2021-05-12
US11766405B2 (en) 2023-09-26
DK3272361T3 (da) 2020-01-27
US20200276128A1 (en) 2020-09-03
ES2648367T3 (es) 2018-01-02
EA036982B1 (ru) 2021-01-22
WO2015059023A1 (de) 2015-04-30
EP3272361B1 (de) 2019-11-20
EP2865391A1 (de) 2015-04-29
HK1208351A1 (en) 2016-03-04
ES2771227T3 (es) 2020-07-06
JP2019043969A (ja) 2019-03-22
JP6461945B2 (ja) 2019-01-30

Similar Documents

Publication Publication Date Title
CL2016002455A1 (es) Anticuerpos multiespecíficos.
EA201690793A1 (ru) Способ получения лиофилизированной фармацевтической композиции, содержащей митомицин c
EA201590887A1 (ru) Композиция
EA202092987A3 (ru) Липид, содержащий докозапентаеновую кислоту
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201892509A1 (ru) Антитела к гемагглютинину и способы применения
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201591748A1 (ru) Модуляторы p2x7
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
EA201491195A1 (ru) Способ получения композиции, содержащей галактоолигосахариды
MX2021010060A (es) Produccion de virus en huevos aviares.
EA201691363A1 (ru) Стабилизированные силикатные композиции и их применение в качестве антиперспирантных композиций
EA201691648A1 (ru) Способ получения противогрибковых соединений
EA201691649A1 (ru) Способ получения противогрибковых соединений
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
EA201591451A1 (ru) Модуляторы flap
MX2015008766A (es) Compuestos cbd fluorados, composiciones y usos de los mismos.
MX345926B (es) Nuevas composiciones, producción de las mismas y uso de las mismas para la producción de poliamidas coladas.
EA201500627A1 (ru) Приготовление стабильного напитка
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства